Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

2023 Human Immunodeficiency Virus (HIV) – US Drug Forecast and Market Analysis

Friday, September 23, 2016 1:56
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science’s Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.
Over the forecast period, the major driver of growth in the US HIV therapeutics market will be the launch of new drugs that offer improvements in terms of the pill burden, tolerability, and efficacy. Novel STRs will have the strongest positive impact on the market, and the drugs within this class of ART regimens include ViiV’s recently launched INI-based STR, Triumeq, which was the first regimen to show superiority over Atripla.

Receive copy of sample report at : https://marketreportscenter.com/request-sample/387683

Scope

- Overview of Human Immunodeficiency Virus (HIV) including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Human Immunodeficiency Virus (HIV) market.

Browse full report with TOC at : https://marketreportscenter.com/reports/387683/human-immunodeficiency-virus-hiv-us-drug-forecast-and-market-analysis-to-2023

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Human Immunodeficiency Virus (HIV).
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the US

Receive Discount at : https://marketreportscenter.com/request-discount/387683

Media contacts:
Sam Collins
Market Reports Center
Call : 1-646-883-3044 (US)
Email : info@marketreportscenter.com
visit our website : https://marketreportscenter.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.